HilleVax (NASDAQ:HLVX) Now Covered by Analysts at SVB Leerink

Investment analysts at SVB Leerink initiated coverage on shares of HilleVax (NASDAQ:HLVXGet Rating) in a research note issued on Tuesday, The Fly reports. The firm set an “outperform” rating on the stock.

Several other research analysts have also recently weighed in on the stock. Guggenheim began coverage on shares of HilleVax in a research report on Tuesday. They set a “buy” rating on the stock. JPMorgan Chase & Co. started coverage on shares of HilleVax in a research report on Tuesday. They set an “overweight” rating on the stock. Finally, Stifel Nicolaus initiated coverage on HilleVax in a research note on Tuesday. They issued a “buy” rating for the company.

NASDAQ:HLVX opened at $9.50 on Tuesday. HilleVax has a one year low of $9.00 and a one year high of $20.95.

HilleVax Company Profile (Get Rating)

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

Further Reading

The Fly logo

Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.